General
Preferred name
tamoxifen
Synonyms
TAMOXIFEN CITRATE ()
trans-Tamoxifen ()
Z-Tamoxifen ()
ICI47699 ()
ICI 46474 ()
ICI 46474 Citrate ()
Tamoxifen Z-isomer citrate ()
Nolvadex ()
TMX ()
Ethanamine, 2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-, (Z)-, 2-hydroxy-1,2,3-propane-tricarboxylate (1:1) ()
Ethanamine, 2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-, (Z)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) ()
Tamoxifen (Citrate) ()
Tamoxifen . citrate ()
(Z)-Tamoxifen (Citrate) ()
trans-Tamoxifen (Citrate) ()
ICI 47699 ()
(Z)-Tamoxifen ()
Tamoxifen (ICI 46474) Citrate ()
Tamoxifen (ICI 46474) ()
Istubal,ICI 46474 Citrate ()
ICI 46474, (Z)-Tamoxifen, trans-Tamoxifen ()
ICI 46,474 ()
Tamofene ()
NSC-180973 ()
Kentadex ()
Nourytam ()
Oestrifen-20 ()
Zemide ()
Fentamox 20 ()
Nolvadex Fte ()
Emblon ()
Zitazonium ()
Kessar 20 ()
Kessar ()
Nolvadex D ()
Fentamox 10 ()
Noltam ()
Kessar 10 ()
NSC-757345 ()
ICI-46474 ()
Oestrifen-40 ()
I.C.I.46474 CITRATE ()
Tamofen ()
Oestrifen-10 ()
Soltamox ()
Zynoplex ()
Tomaxasta ()
Tamoxifeni citras ()
[3H]tamoxifen ()
Novaldex ()
Mammaton ()
ICI-47699 ()
Tamoplex ()
NSC-727681 ()
Tamoxifen-d5 ()
P&D ID
PD003610
CAS
10540-29-1
157698-32-3
7244-97-5
54965-24-1
Tags
available
prodrug
drug
Approved by
FDA
First approval
1977
Drug Status
approved
Drug indication
Anti-Estrogen
Breast cancer
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Tamoxifen can be classed as a mixed agonist/antagonist of the estrogen -α and -β receptors, as its activity is depends on the tissue in which the receptor is expressed. ChEMBL classify this compound as an estrogen receptor alpha modulator, while it is described as a selective estrogen receptor modulator by Burris et al. in their 2013 review .
DESCRIPTION Tamoxifen can be classed as a mixed agonist/antagonist of the estrogen -α and -β receptors, as its activity depends on the tissue in which the receptor is expressed. ChEMBL classify this compound as an ERα modulator, while it is described as a selective estrogen receptor modulator by Burris et al. in their 2013 review . Tamoxifen can be considered as a prodrug as its three main metabolites exhibit higher affinity and specificity than tamoxifen at the ERα and ERβ receptors. (GtoPdb)
DESCRIPTION modulator of estrogen receptors (Informer Set)
DESCRIPTION Estrogen receptor antagonist (Tocris Bioactive Compound Library)
DESCRIPTION Estrogen receptor partial agonist/antagonist (Tocriscreen Plus)
DESCRIPTION Anti-estrogen; relatively selective protein kinase C inhibitor (LOPAC library)
DESCRIPTION Glucocorticoid antiasthmatic prodrug (Tocris Bioactive Compound Library)
DESCRIPTION Estrogen receptor partial agonist/antagonist (Tocriscreen Total)
Cell lines
42
Organisms
7
Compound Sets
39
AdooQ Bioactive Compound Library
A10885
A16738
Axon Medchem Screening Library
3252
Cayman Chemical Bioactives
11629
13258
27190
18262
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
CHEMBL786
CHEMBL83
ChEMBL Drugs
CHEMBL786
CHEMBL83
Concise Guide to Pharmacology 2017/18
1016
Concise Guide to Pharmacology 2019/20
1016
Concise Guide to Pharmacology 2021/22
1016
Concise Guide to Pharmacology 2023/24
1016
Drug Repurposing Hub
DrugBank
DB00675
DrugBank Approved Drugs
DB00675
DrugCentral
2561
DrugCentral Approved Drugs
2561
DrugMAP
DMLB0EZ
DrugMAP Approved Drugs
DMLB0EZ
Enamine BioReference Compounds
Guide to Pharmacology
1016
5384
Informer Set
26972
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL83
Mcule NIBR MoA Box Subset
MCULE-8346437605
MedChem Express Bioactive Compound Library
HY-13757
HY-13757A
NCATS Inxight Approved Drugs
094ZI81Y45
NIH Approved Oncology Drugs
447264
NIH Mechanistic Set
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
NURSA ligand set
nursa/index.jsf?doi=10.1621%2F84RTZ5I395
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Nolvadex
Tamoxifen-Citrate(Nolvadex)
TargetMol Bioactive Compound Library
T0835
T6906
The Spectrum Collection
Tocris Bioactive Compound Library
0999
6342
Tocriscreen Plus
0999
Tocriscreen Total
Welcome Trust Cancer Drugs
1199
External IDs
82
Properties
(calculated by RDKit )
Molecular Weight
371.22
Hydrogen Bond Acceptors
2
Hydrogen Bond Donors
0
Rotatable Bonds
8
Ring Count
3
Aromatic Ring Count
3
cLogP
6.0
TPSA
12.47
Fraction CSP3
0.23
Chiral centers
0.0
Largest ring
6.0
QED
0.45
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
ESR1
ESR2
ER
Estrogen receptor alpha
estrogen receptor
EBP, ESR1, ESR2, GPER1, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PRKCI, PRKCQ, PRKCZ
SERM
Estrogen Receptor/ERR
HSP
Apoptosis related,Autophagy,Estrogen/progestogen Receptor,HSP (HSP90)
Antineoplastic and Immunosuppressive Antibiotics,Apoptosis related,ATPase,Autophagy,Estrogen/progestogen Receptor,HSP (HSP90)
Compound status
FDA
Target Type
Nuclear Receptors
Selectivity
PKC
MOA
Estrogen Receptor antagonist
Modulator
Estrogen/Progestogen Receptor antagonist
Selective Estrogen Receptor Modulator (SERM)
estrogen receptor antagonist, selective estrogen receptor modulator (SERM)
Pathway
Angiogenesis
Endocrinology/Hormones
Apoptosis
Autophagy
Cell Cycle/DNA Damage
Metabolic Enzyme/Protease
Vitamin D Related/Nuclear Receptor
Primary Target
Estrogen and Related Receptors
Member status
member
Indication
breast cancer
Therapeutic Class
Anticancer Agents
Source data